Stay updated with breaking news from Stephens Yoder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM ESTInitiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this yearDosed first patient in
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDTDosing completed in part 1a of phase 2a study of PRS-060/AZD1402Dosing to begin this quarter in phase 2 study of cinrebafusp
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech ACCESSWIRE 25 May 2021, 22:05 GMT+10 Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs BOSTON, MA / ACCESSWIRE / May 25, 2 021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biother...